📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Orphazyme

1.1 - Company Overview

Orphazyme Logo

Orphazyme

Headquarter: Denmark
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of biopharmaceutical R&D for novel therapeutics targeting lysosomal storage diseases and other genetic disorders; conducts clinical trials, offers early access programs for investigational drugs, and delivers safety reporting/pharmacovigilance. Developed arimoclomol for neurodegenerative diseases, including Niemann Pick disease type C (sold to KemPharm Denmark A/S).

Products and services

  • Biopharmaceutical Research and Development: Engineers novel therapeutics for genetic disorders, focusing on lysosomal storage diseases with activities and investments grounded in founders’ Danish Cancer Society discoveries
  • Research-grade
  • Clinical Trials: Conducts studies to evaluate efficacy and safety of compounds for treating genetic disorders, supporting advancement of lysosomal storage disease therapies through patient investigations
  • Clinical-stage
  • Early Access Program: Delivers access to investigational drugs outside clinical trials for patients with serious conditions, enabling treatment availability while formal studies progress
  • Investigational

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Orphazyme

Chord Therapeutics Logo

Chord Therapeutics

HQ: Switzerland Website
  • Description: Provider of clinical-stage biopharmaceutical drug development for rare, life-threatening and severely disabling diseases, advancing lead candidate CRD1 under orphan drug designation for neuromyelitis optica spectrum disorders (NMOSD) and myasthenia gravis (MG).
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Chord Therapeutics company profile →
Perlara Logo

Perlara

HQ: United States Website
  • Description: Provider of precision drug discovery services: drug repurposing screening to identify potential treatments and advise on experimentation and clinical translation; CureMap disease analyses with literature review, ongoing research, expert interviews, and partner identification; scientific advisory for reviews, client meetings with scientific partners, and translation guidance; and Guided Cures planning with researchers and clinicians.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Perlara company profile →
ProFactor Pharma Logo

ProFactor Pharma

HQ: United Kingdom Website
  • Description: Provider of recombinant blood factors for haemophilia, including a low-cost, GMP-optimized recombinant human Factor VIII (rhFVIII) for Haemophilia A. Offers a patent-protected cell line and production process delivering higher yields and lower costs, and collaborates with Bio Farma Persero on scale-up, clinical trials planned to commence in 2024, and commercialization.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full ProFactor Pharma company profile →
Evox Therapeutics Logo

Evox Therapeutics

HQ: United Kingdom Website
  • Description: Provider of engineered exosome-based delivery and therapeutics via its DeliverEX platform to modify exosomes, load drugs, and target delivery to specific organs. Solutions include treatments for rare diseases, exosome-enabled gene therapy (AAV cloaking), gene editing with CRISPR, RNA therapeutics, and precision targeting to the brain and central nervous system.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Evox Therapeutics company profile →
Actio Biosciences Logo

Actio Biosciences

HQ: United States Website
  • Description: Provider of rare disease drug discovery and development, with a small molecule TRPV4 program for Charcot-Marie-Tooth disease type 2C and serious bone diseases; a proprietary Rare Disease Target Atlas for target identification and function; a partnership with The Jackson Laboratory to create transgenic models for target evaluation and phenotype analysis; and upcoming programs for genetic epilepsies and genetic skin conditions.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Actio Biosciences company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Orphazyme

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Orphazyme

2.2 - Growth funds investing in similar companies to Orphazyme

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Orphazyme

4.2 - Public trading comparable groups for Orphazyme

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Orphazyme

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Orphazyme

What does Orphazyme do?

Orphazyme is a provider of biopharmaceutical R&D for novel therapeutics targeting lysosomal storage diseases and other genetic disorders; conducts clinical trials, offers early access programs for investigational drugs, and delivers safety reporting/pharmacovigilance. Developed arimoclomol for neurodegenerative diseases, including Niemann Pick disease type C (sold to KemPharm Denmark A/S).

Who are Orphazyme's competitors?

Orphazyme's competitors and similar companies include Chord Therapeutics, Perlara, ProFactor Pharma, Evox Therapeutics, and Actio Biosciences.

Where is Orphazyme headquartered?

Orphazyme is headquartered in Denmark.

How many employees does Orphazyme have?

Orphazyme has 1,000 employees 🔒.

When was Orphazyme founded?

Orphazyme was founded in 2010 🔒.

What sector and industry vertical is Orphazyme in?

Orphazyme is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Orphazyme

Who are the top strategic acquirers in Orphazyme's sector and industry

Top strategic M&A buyers and acquirers in Orphazyme's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Orphazyme?

Top strategic M&A buyers groups and sectors for Orphazyme include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Orphazyme's sector and industry vertical

Which are the top PE firms investing in Orphazyme's sector and industry vertical?

Top PE firms investing in Orphazyme's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Orphazyme's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Orphazyme's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Orphazyme's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Orphazyme include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Orphazyme's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Orphazyme?

The key public trading comparables and valuation benchmarks for Orphazyme include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Orphazyme for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Orphazyme with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Orphazyme's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Orphazyme with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Orphazyme's' sector and industry vertical?

Access recent funding rounds and capital raises in Orphazyme's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Orphazyme